REG - AstraZeneca PLC - AZN invests $2.5bn in Beijing R&D & manufacturing

AstraZenecaAnnouncement

21/03/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250321:nRSU6959Ba&default-theme=true

RNS Number : 6959B  AstraZeneca PLC  21 March 2025

21 March 2025

 

AstraZeneca to invest $2.5 billion in new global strategic R&D centre,
biotech agreements and manufacturing in Beijing

 

AstraZeneca is establishing a new global strategic R&D centre in Beijing,
its second in China and sixth worldwide

 

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and
BioKangtai

 

AstraZeneca today announced an investment of $2.5 billion in Beijing to
establish its sixth global strategic R&D centre together with major
research and manufacturing agreements that will further advance life sciences
in China. This investment over the next five years is part of a strategic
partnership with the Beijing Municipal Government and the Beijing
Economic-Technological Development Area Administrative Office and includes
agreements with three biotechs; Harbour BioMed, Syneron Bio, and BioKangtai,
and follows the recent Fibrogen announcement. AstraZeneca expects its Beijing
workforce to grow to 1,700 employees.

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: This $2.5 billion
investment reflects our belief in the world-class life sciences ecosystem in
Beijing, the extensive opportunities that exist for collaboration and access
to talent, and our continued commitment to China. Our sixth strategic R&D
centre will partner with the cutting-edge biology and AI science in Beijing
and be a critical part of our global efforts to bring innovative medicines to
patients worldwide.

 

The new global strategic R&D centre in Beijing, AstraZeneca's second in
China following the opening of the Shanghai R&D centre, will advance
early-stage research and clinical development and will be enabled by a new
state-of-the-art AI and data science laboratory. The new R&D centre will
be located near leading biotechs, research hospitals, and the National
Medical Products Administration in the Beijing International Pharmaceutical
Innovation Park (BioPark).

 

AstraZeneca is also establishing new R&D collaborations in Beijing. This
includes a strategic partnership with the Beijing Cancer Hospital in
translational research, data science, and clinical development. AstraZeneca is
signing two collaboration and licensing agreements; one with Harbour BioMed to
discover multi-specific antibodies, and one with Syneron Bio to develop
macro-cyclic peptides.

 

In addition, AstraZeneca is launching a new joint venture with BioKangtai, to
develop, manufacture, and commercialise innovative vaccines for respiratory
and other infectious diseases for patients in China and around the world. This
will be AstraZeneca's first and only vaccine manufacturing facility in China,
which will be located in the Beijing BioPark.

 

To support the development of the Beijing innovation ecosystem, Pascal Soriot,
CEO AstraZeneca, has been invited to join the Beijing International Business
Leaders Advisory Council (IBLAC).

 

Notes

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://astrazeneca.com) and follow the Company
on social media @AstraZeneca (https://www.linkedin.com/company/astrazeneca/)
.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFEIVEILFIE